Straight to the heart: Protecting the patient's heart during chemotherapy

Rachel Conyers; David A Elliott

doi:10.1016/j.stem.2024.10.010

Straight to the heart: Protecting the patient's heart during chemotherapy

Cell Stem Cell. 2024 Dec 5;31(12):1715-1716. doi: 10.1016/j.stem.2024.10.010.

Authors

Rachel Conyers¹, David A Elliott²

Affiliations

¹ Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; Children's Cancer Centre, Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC, Australia.
² Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; The Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Murdoch Children's Research Institute, Parkville, VIC, Australia; Australian Regenerative Medicine Institute, Monash University, Wellington Road, Clayton, VIC, Australia. Electronic address: david.elliott@mcri.edu.au.

PMID: 39642857
DOI: 10.1016/j.stem.2024.10.010

Abstract

How do we protect the heart during chemotherapy with the anthracycline drug class? Tackling this question, Liu et al. combined pluripotent stem cell models, CRISPR genetic screens, and molecular modeling to identify indisulam as a potential cardioprotective drug in this issue of Cell Stem Cell.

Publication types

Comment

MeSH terms

Anthracyclines
Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Cardiotonic Agents / pharmacology
Cardiotonic Agents / therapeutic use
Heart / drug effects
Humans

Substances

Antineoplastic Agents
Anthracyclines
Cardiotonic Agents